Formulation and evaluation loaded nanoparticles of dorzolamide hydrochloride

Abstract

Objective: The study aimed to formulate and evaluate Dorzolamide Hydrochloride-loaded nanoparticles to enhance ocular bioavailability and therapeutic efficacy. The formulation utilized Eudragit RSPO and Poloxamer 188 as polymers to optimize nanoparticle characteristics and drug release profiles.

Methods: Dorzolamide Hydrochloride nanoparticles were prepared using a nanoprecipitation technique involving Eudragit RSPO and Poloxamer 188. Various formulation parameters were optimized to achieve the desired particle size, drug loading capacity. The nanoparticles were characterized for their physical properties, including size, and zeta potential. In-vitro drug release studies were conducted to evaluate the release profile of the drug from the nanoparticles.

Results: Among the different formulations tested, the formulation with Eudragit RSPO and Poloxamer 188 F2 exhibited the most favorable characteristics. The F2 formulation achieved an in-vitro drug release of 99.37%, indicating a high release efficiency and sustained release profile. This formulation was considered optimal based on its drug release performance and stability.

Conclusion: The developed Dorzolamide Hydrochloride-loaded nanoparticles using Eudragit RSPO and Poloxamer 188 demonstrated excellent drug release characteristics. The F2 formulation, with its high in-vitro release rate, holds promise for improving the ocular delivery of Dorzolamide Hydrochloride, potentially enhancing its therapeutic efficacy and reducing side effects associated with conventional dosage forms.